Patient and injury characteristics
| Characteristic | |
| Age | 45 (32–61) |
| Male | 111 (84.7%) |
| Race | |
| White | 72 (55.0%) |
| Black | 15 (11.5%) |
| Asian | 3 (2.3%) |
| American Indian/Alaskan Native | 6 (4.6%) |
| Unknown | 35 (26.7%) |
| Hispanic | 50 (38.2%) |
| Comorbidities | |
| Diabetes | 27 (20.6%) |
| COPD | 9 (6.9%) |
| HD dependent | 1 (0.8%) |
| CHF | 6 (4.6%) |
| Active cancer | 4 (3.1%) |
| HIV/AIDS | 0 (0%) |
| Cirrhosis | 2 (1.5%) |
| None of the above | 85 (64.9%) |
| Unknown | 8 (6.1%) |
| Smoking status | |
| Smoker | 59 (45.0%) |
| Non-smoker | 47 (35.9%) |
| Unknown | 25 (19.1%) |
| ISS | 18 (14–30) |
| Blunt vs. penetrating injury | |
| Blunt | 114 (87.0%) |
| Penetrating | 17 (13.0%) |
| Type of injury | |
| TBI | 91 (69.5%) |
| Chest trauma | 70 (53.4%) |
| Pelvic or long-bone fracture | 43 (32.8%) |
| Abdominal organ trauma | 27 (20.6%) |
| Spinal cord injury | 44 (33.6%) |
| Type of pneumonia | |
| CAP | 29 (22.1%) |
| HAP | 19 (14.5%) |
| VAP | 83 (63.4%) |
| Hospital day of pneumonia diagnosis | 4 (3,6) |
| White cell count | 11.9 (0.44) |
| Temperature | 38.4 (0.07) |
| Prophylactic antibiotics before cultures drawn | |
| Any | 67 (51.1%) |
| Gentamicin | 5 (3.8%) |
| Cefazolin | 33 (25.2%) |
| Cefuroxime | 37 (28.2%) |
| Cefoxitin | 6 (4.6%) |
| Other | 2 (1.5%) |
| Treatment antibiotics before cultures drawn | |
| Any | 23 (17.6%) |
| Ceftriaxone | 5 (3.8%) |
| Piperacillin/tazobactam | 10 (7.6%) |
| Vancomycin | 7 (5.3%) |
| Other | 2 (1.5%) |
Results are presented as n (%), mean (SD), or median (IQR) as appropriate.
CAP, community-acquired pneumonia; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; HAP, hospital-acquired pneumonia; HD, hemodialysis; ISS, Injury Severity Score; TBI, traumatic brain injury; VAP, ventilator-associated pneumonia.;